Who is sponsoring NCT02503358?

NCT02503358 is sponsored by OHSU Knight Cancer Institute.

What drugs are being tested in NCT02503358?

Interventions in NCT02503358: Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Selumetinib.

What condition does NCT02503358 study?

NCT02503358 studies Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7.

Is NCT02503358 still recruiting?

NCT02503358 is currently completed. Last updated 21 March 2023.

Last reviewed 2023-03-21 · How we verify

NCT02503358

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Completed Phase 1 Last updated 21 March 2023

What this trial tests

Phase 1 trial testing Laboratory Biomarker Analysis in Stage IIIB Non-Small Cell Lung Cancer AJCC v7 in 23 participants. Completed in 16 July 2020.

Timeline

21 July 2016

Primary endpoint
16 July 2020

16 July 2020

Quick facts

Lead sponsor	OHSU Knight Cancer Institute
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	21 July 2016
Primary completion	16 July 2020
Estimated completion	16 July 2020
Sites	1 location across United States

Drugs / interventions tested

Laboratory Biomarker Analysis
Paclitaxel — full drug profile →
Pharmacological Study — full drug profile →
Selumetinib — full drug profile →

Conditions studied

Stage IIIB Non-Small Cell Lung Cancer AJCC v7 — all drugs for Stage IIIB Non-Small Cell Lung Cancer AJCC v7 →
Stage IV Non-Small Cell Lung Cancer AJCC v7 — all drugs for Stage IV Non-Small Cell Lung Cancer AJCC v7 →

Sponsor

OHSU Knight Cancer Institute

Who can join

18 and older, any sex, with Stage IIIB Non-Small Cell Lung Cancer AJCC v7 or Stage IV Non-Small Cell Lung Cancer AJCC v7. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized phase I trial is studying the side effects and the best dose of selumetinib when given together with paclitaxel as a second line therapy in treating patients with stage IIIB-IV non-small cell lung cancer (NSCLC). Selumetinib may stop or slow the growth of tumor cells by blocking a protein called mitogen-activated protein kinase (MEK) that is needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving selumetinib together with paclitaxel may kill more tumor cells.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC.
Xia M, Li X, Diao Y, Du B, et al · · 2021 · cited 33× · PMID 33137541 · DOI 10.1016/j.tranon.2020.100920
PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures.
Emon MA, Domingo-Fernández D, Hoyt CT, Hofmann-Apitius M. · · 2020 · cited 10× · PMID 32503412 · DOI 10.1186/s12859-020-03568-5

Verify or expand the search:

Other trials of Laboratory Biomarker Analysis

Trials testing the same drug.

NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men · withdrawn
NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men · withdrawn
NCT05558904 — An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cance · Phase 1, PHASE2 · recruiting
NCT05564650 — Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome · Phase 1 · active not recruiting
NCT05396859 — Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia · Phase 1 · active not recruiting

Other OHSU Knight Cancer Institute trials

Trials by the same sponsor.

NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme · Phase 1, PHASE2 · not yet recruiting
NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting
NCT07434128 — Mammogram Pretreatment With Ulipristal Acetate · Phase 2 · not yet recruiting
NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02503358 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by OHSU Knight Cancer Institute
Last refreshed: 21 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02503358.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing